IP Library Granted Patent US 8,889,185
Granted Patent B2
US 8,889,185 · App. 14/079,414 · Granted Nov 18, 2014

Modified release compositions comprising tacrolimus

Inventors: Per Holm (Vanlose, DK); Tomas Norling (Lyngby, DK)
Assignee: Veloxis Pharmaceuticals A/S
A61K9/0053A61K9/1617A61K9/1623A61K9/1641A61K9/1652A61K9/2013A61K9/2018A61K9/2027A61K9/2031A61K9/2054A61K9/2077A61K9/2846A61K31/00A61K31/436A61K31/4745A61K9/10A61K31/439A61K9/1611A61K9/2009A61K9/2095A61K9/2893Y10S514/885
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,889,185
App. No.
14/079,414
Granted
Nov 18, 2014
Kind
B2
Abstract

A modified release composition comprising tacrolimus which is useful for the treatment or prevention of rejection reactions by transplantation of organs or tissues.

Claims (29)

1. A method of suppressing a rejection reaction by transplantation of an organ in a patient, the method comprising orally administering to the patient an oral, once daily, extended release pharmaceutical composition comprising tacrolimus wherein the in vivo release of the extended release pharmaceutical composition after oral administration takes place substantially in the lower gastrointestinal tract, and the pharmaceutical composition provides a W 50 (the time where the plasma concentration is 50% or more of C max ) of at least 10 hours.

2. The method of claim 1 , wherein the pharmaceutical composition provides a W 50 of at least 11 hours.

3. The method of claim 2 , wherein the pharmaceutical composition provides a W 50 of at least 12 hours.

4. The method of claim 3 , wherein the pharmaceutical composition provides a W 50 of at least 13 hours.

5. The method of claim 4 , wherein the pharmaceutical composition provides a W 50 of at least 14 hours.

6. A method of suppressing a rejection reaction by transplantation of an organ in a patient, the method comprising orally administering to the patient an oral, once daily, extended release pharmaceutical composition comprising tacrolimus wherein the in vivo release of the extended release pharmaceutical composition after oral administration takes place substantially in the lower gastrointestinal tract, and the pharmaceutical composition provides an AUC fed /AUC fasted of at least about 0.9.

7. The method of claim 6 , wherein the pharmaceutical composition comprises a modifying release agent.

8. The method of claim 6 , wherein the pharmaceutical composition is in the form of a compressed tablet.

9. The method of claim 6 , wherein the extended release pharmaceutical composition is designed to substantially avoid CYP3A4 metabolism in the gastrointestinal tract upon oral administration.

10. The method of claim 8 , wherein the extended release pharmaceutical composition provides a zero order release profile.

11. A method of suppressing a rejection reaction by transplantation of an organ in a patient, the method comprising orally administering to the patient an oral, once daily, extended release pharmaceutical composition comprising tacrolimus wherein the in vivo release of the extended release pharmaceutical composition after oral administration takes place substantially in the lower gastrointestinal tract, and the oral administration of the composition results in a plasma concentration of about 5 ng/mL to about 20 ng/mL for at least about 24 hours.

12. The method of claim 11 , wherein the pharmaceutical composition comprises a solid dispersion or solid solution of tacrolimus.

13. The method of claim 11 , wherein the pharmaceutical composition provides a W 50 of at least 11 hours.

14. The method of claim 13 , wherein the pharmaceutical composition provides a W 50 of at least 12 hours.

15. The method of claim 14 , wherein the pharmaceutical composition provides a W 50 of at least 13 hours.

16. The method of claim 15 , wherein the pharmaceutical composition provides a W 50 of at least 14 hours.

17. The method of claim 1 , wherein the extended release pharmaceutical composition provides a zero order release profile.

18. The method of claim 6 , wherein the extended release pharmaceutical composition provides a zero order release profile.

19. The method of claim 11 , wherein the extended release pharmaceutical composition provides a zero order release profile.

20. The method of claim 1 , wherein the patient is a kidney transplant patient.

21. The method of claim 1 , wherein the patient is a liver transplant patient.

22. The method of claim 6 , wherein the patient is a kidney transplant patient.

23. The method of claim 6 , wherein the patient is a liver transplant patient.

24. The method of claim 11 , wherein the patient is a kidney transplant patient.

25. The method of claim 11 , wherein the patient is a liver transplant patient.

26. The method of claim 18 , wherein the patient is a kidney transplant patient.

27. The method of claim 18 , wherein the patient is a liver transplant patient.

28. The method of claim 19 , wherein the patient is a kidney transplant patient.

29. The method of claim 19 , wherein the patient is a liver transplant patient.

Assignments (7)
CHANGE OF ADDRESS Recorded Jun 7, 2024
From: VELOXIS PHARMACEUTICALS INC.
To: VELOXIS PHARMACEUTICALS INC.
Reel/Frame 067666/0352 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2021
From: VELOXIS PHARMACEUTICALS A/S
To: VELOXIS PHARMACEUTICALS INC.
Reel/Frame 055815/0597 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2021
From: VELOXIS PHARMACEUTICALS A/S,
To: VELOXIS PHARMACEUTICALS INC.
Reel/Frame 055613/0695 →
RELEASE OF SECURITY INTEREST Recorded Jan 23, 2020
From: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
To: VELOXIS PHARMACEUTICALS A/S
Reel/Frame 051602/0704 →
RELEASE OF SECURITY INTEREST Recorded Mar 2, 2018
From: LUNDBECKFOND INVEST A/S; NOVO A/S
To: VELOXIS PHARMACEUTICALS A/S
Reel/Frame 045093/0727 →
SECURITY INTEREST Recorded Feb 15, 2018
From: VELOXIS PHARMACEUTICALS A/S
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
Reel/Frame 044942/0597 →
SECURITY INTEREST Recorded Apr 12, 2016
From: VELOXIS PHARMACEUTICALS A/S
To: NOVO A/S; LUNDBECKFOND INVEST A/S
Reel/Frame 038256/0318 →
Priority Claims (5)
DK 2003 01232 · Aug 29, 2003 · national
DK 2003 01837 · Dec 11, 2003 · national
DK 2004 00079 · Jan 21, 2004 · national
DK 2004 00463 · Mar 23, 2004 · national
DK 2004 00467 · Mar 23, 2004 · national
Continuity (3)
Continuation 10569862
Provisional Application 60529793 · Dec 15, 2003
Related Publication 20140073665A1 · Mar 13, 2014